EUVIMEDOntdek EUVIMED
CrossrefInfokaart

1‐Deoxynojirimycin Alleviates Osteoporosis via Promoting LRP5 Signaling in Osteoblasts and BMSCs

Kainong Sun, Yuru Li, Ke Zhao, Jiayang Xu, Robert J. Tower, Meng Shen, Wanhan Zhang, Wei Xiong, Kai Li, Bo Li, Qian Zhang

Phytotherapy Research · 2026-11-09

DOI: 10.1002/ptr.70508 ↗
SamenvattingBibliografische gegevens

Samenvatting

ABSTRACT Osteoporosis is the most common bone disease worldwide, and natural bioactive products that promote osteogenesis are a therapeutic strategy to prevent osteoporosis. 1‐Deoxynojirimycin (DNJ) is the major bioactive small molecule in mulberry with anti‐diabetic properties, but its effect on osteoporosis treatment remains largely unexplored. This study aims to investigate the effects and underlying mechanisms of DNJ on osteoporosis, with a particular emphasis on its ability to promote osteogenesis pathways. We investigated the bone anabolic ability of DNJ in two well‐recognized osteoporosis models: ovariectomy‐induced and high‐fat diet (HFD)‐induced osteoporosis. DNJ prevented estrogen deficiency and HFD‐induced bone loss, resulting in increased osteoblast number and inhibited osteoclast number, supporting its therapeutic potential for osteoporosis. Consistent with these in vivo results, in vitro experiments showed that DNJ promoted osteogenic differentiation and matrix mineralization of primary BMSCs and osteoblasts without affecting primary osteoclast differentiation. Mechanistic studies revealed that DNJ increased osteoblastic mineralization by directly binding to the extracellular domain of the transmembrane protein LRP5, thus promoting the Wnt/β‐catenin signaling axis to activate the transcription of osteogenesis‐related genes in osteoblasts. Taken together, our study demonstrated that DNJ plays a critical role in activating the LRP5/β‐catenin pathway, suggesting its potential as a candidate for osteoporosis prevention and treatment.

Kennis die bij uw werk past.

Van een gratis start via persoonlijk literatuuronderzoek tot de volledige Research Suite.

Tarieven bekijken →

Zijn alle volledige uitgeversteksten inbegrepen?

Nee. Bibliografische records, abstracts en volledige teksten zijn verschillende inhoudstypen. Beschikbaarheid hangt af van bron, open access en bestaande licenties. Een EUVIMED-abonnement vervangt geen aanvullende uitgeversrechten.

Tarieven bekijken →